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Introduction
Incidence of graft infection after arterial reconstructive
surgery lies within the range of 0.5 to 26%.1 – 3 In last
decade, proportion of graft infection with methicillin-
resistant Staphylococcus aureus (MRSA) has increased.4
It is associated with high amputation and mortality
rate especially Szylagyi type III graft infection.5,6
MRSA prosthetic graft infection is now considered as
an absolute induction of complete graft excision.7 This
case presents a more conservative approach with use
of new antibiotic linezolid in the treatment of Szylagyi
type III graft infection.
Case Report
A 61-year-old male had Aorto-biiliac graft in October
1999, to treat aortic and iliac aneurysms. After 1 year,
he presented with right leg claudication at 20 yards.
Arteriography showed blocked right external iliac
artery and bilateral femoral artery aneurysm of 5 cm
size diameter. Left side femoral artery aneurysm was
repaired by in-lay Dacron graft and a covered Dacron
graft of 8 mm diameter was used for left to right
femoro-femoral crossover bypass. He received anti-
biotic ceftriaxone 1 gm once daily and metronidazole
500 mg three times a day given intravenous for 5 days
started from immediate preoperative period. The post
operative recovery was uneventful with no signs of
infection in groin wound on discharge from hospital
after 9 days post operatively.
One month later, he presented with right groin
swelling and cellulitis. CT scan showed 5 £ 3 cm
abscess in the suprapubic area in relation to crossover
graft and a 3 cm size collection in right groin around
the anastomosis (Szylagyi type III) (Fig. 1). There was
no CT scan evidence of extension of the abscess to
aorto-biiliac graft. Duplex scan showed adequate flow
through the graft and both femoral arteries. The
suprapubic abscess was aspirated and the patient
was started on intravenous antibiotics (cefuroxime
and metronidazole). The culture from aspirate
revealed MRSA. Both Right groin and suprapubic
abscess later opened on to the skin and repeat culture
from it also grew MRSA. There was high risk of
extension of this abscess to the aorto-biiliac graft along
the retro-peritoneum. The patient was advised to have
excision of femoral crossover graft and repair of
femoral arteries with vein patch followed by delayed
bypass graft to his right leg. He refused to have any
surgical intervention considering the risk of ischaemia
of the right leg.
The new antibiotic for MRSA, linezolid was given in
a dose of 600 mg twice a day intravenously for 2
weeks. Repeat cultures from the wound discharge
were negative for MRSA after a week of commencing
linezolid. Patient was than given further 2 weeks
therapy of oral linezolid and discharged home. After 1
month, he presented with left groin swelling and
cellulitis. Ultra-sound scan confirmed a 2.3 cm size
abscess in relation to left side graft anastomosis, which
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was drained and culture again showed MRSA. Right
side groin and suprapubic wound were healed and
did not have any clinical signs of infection. USG scan
did not show any collection in right groin and
suprapubic area. This time, it was treated by linezolid
in combination with teicoplanin (400 mg intravenous
daily after loading dose) for 2 weeks and followed by
oral tetracycline and function for 4 weeks. Follow up
ultrasound scan at 3, 6, 12 and 18 months showed no
recurrence of abscess and functioning graft (Fig. 2). At
the time of 18 months follow up, USG scan guided
multiple needle aspirates (18G needle) were taken
from the tissue around the graft from previous abscess
sites under local anaesthesia and send for culture. All
the cultures were sterile and a CT scan done at 18
months review did not show any recurrence of
abscess.
Discussion
Staphylococcus is most common cause of nosocomial
infection. In last decade there has been increase in
methicillin resistance in Staphylococcus from 1.7% in
1990 to 34% in 1998.8,9 Incidence of MRSA vascular
graft infection ranges from 9 to 37%.4 – 6 Most vascular
surgeon would consider complete graft excision of an
infected infra-inguinal bypass graft in the presence of
a false aneurysm, sepsis and graft occlusion. MRSA
infection is also now considered an absolute indication
for prosthetic graft excision if it is Szylagyi III
infection, as it is associated with high incidence of
mortality.6,7
Previously used treatment with vancomycin and
teicoplanin does not seem to be successful to reduce
mortality and amputation rate in MRSA graft infec-
tion. A prospective audit of MRSA graft infection
showed 75% death or amputation rate in type III
infection. The evidence from audit suggested in
Szylagyi type III MRSA infection is present in a
prosthetic graft than primary treatment should be
graft excision and amputation with aim to preserve life
rather than limb.6
There have been few reports in literature on
successful treatment of vascular graft infection by
antibiotics alone.10,11 Although traditional manage-
ment remains surgical intervention but in selected
cases antibiotic therapy alone could be valuable tool in
the management of prosthetic graft infection. In our
case, we had to choose conservative approach as
patient strongly opposed surgical debridement and
excision of his crossover graft in fear of possible
ischaemia of his right leg.
Linezolid is an oxazolidone antimicrobial agent
specifically reserved to use against MRSA, especially
against vancomycin resistant strain. It acts by inhibit-
ing the initiation step of protein synthesis and is not
cross resistant to other drugs.12 The recommended
dose is 600 mg intravenously or orally every 12 h.
There have been reports of successful treatment of his
prosthetic infection due to MRSA with linezolid.13 It
has been found to be equally effective or superior to
vancomycin against MRSA infection in double blind
randomised studies.14,15
There was complete resolution of abscess (Szylagyi
III) in relation to graft anastomosis and healing of
discharging sinuses with linezolid therapy in our
reported case. At initial presentation we treated
infection with linezolid alone but on second presen-
tation on other side it was combined with teicoplanin
to increase the efficacy of treatment and also to prevent
emergence of resistant strain. More so, once bacteria
Fig. 1. CT scan showing groin abscess in relation to graft
(arrow).
Fig. 2. Ultrasound scan after treatment showing complete
resolution of abscess in relation to graft.
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adhere to graft a biofilm may develop around and
protect it from host defences and antibiotics.
The bacteria living in outer layer of biofilm are
active and susceptible to some degree to antibiotics.
When bacterias in the outer layer of biofilm
approaches to a critical mass, they are released to
cause acute infection.16 It is important to give prolong
antibiotic therapy in attempt to eliminate bacterias in
outer layer which are relevant to symptomatic graft
infection.
The follow up proved that treatment was effective
with no recurrence. The MRSA may remain dormant
in the tissues for considerable time so we did needle
aspiration and culture of tissue from previous infec-
tion sites after 18 months of treatment all of which
proved sterile. We conclude that linezolid can be
successfully used in selected cases of MRSA vascular
graft infection preferably in combination with other
antibiotics.
References
1 Lorentzen JE, Nielsen OM, Arendrup H et al. Vascular graft
infection: an analysis of 62 graft infections in 2411 consecutively
implanted synthetic vascular grafts. Surgery 1985; 98: 81–86.
2 Yeager RA, Porter JM. Arterial and prosthetic graft infection.
Ann Vasc Surg 1992; 6: 485–491.
3 Calligra KD, Veith F. Diagnosis and management of infected
prosthetic aortic grafts. Surgery 1991; 110: 805–813.
4 Nasim A, Thompson MM, Naylor AR, Bell PRF, London NJM.
The impact of MRSA on vascular surgery. Eur J Vasc Endovasc
Surg 2001; 22: 211–214.
5 Murphy GJ, Pararajasingam R, Nasim A, Dennis MJ, Sayer
RD. Methicillin-resistant Staphylococcus aureus infection in vas-
cular surgical patients. Ann R Coll Surg Engl 2001; 83: 158–163.
6 Naylor AR, Hayes PD, Darke S. A prospective audit of complex
wound and graft infections in Great Britain and Ireland: the
emergence of MRSA. Eur J Vasc Endovasc Surg 2001; 21: 289–294.
7 Chalmers RTA, Wolfe JHN, Cheshire NJW et al. Improved
management of infrainguinal bypass graft infection with
methicillin-resistant Staphylococcus aureus. Br J Surg 1999; 86:
1433–1436.
8 National Nosocomial Infection Surveillance (NNIS) Report, Data
from October 1986 to April, issued May 1996. Am J Infect Control
1996; 24: 380–388.
9 Reacher MH, Shah A, Livermore DM et al. Bacteraemia and
antibiotic resistance of its pathogens reported in England and
Wales between 1990 and 1998: trend analysis. BMJ 2000; 320:
213–216.
10 Wilkinson JM, Munro EN, Welsh CL, Coen LD. Successful non
operative management of late infrainguinal polytetrafluoroethy-
lene vascular graft infection with antibiotics alone: a report of
two cases. Panminerva Medica 1997; 39: 128–131.
11 Bellelli G, Barbisoni P, Rozzini R, Trabucchi M. A rare case of
successful antibiotic therapy in an elderly man with a retarded
aorto-bifemoral graft infection. Aging (Milano) 1999; 11: 277–278.
12 Zurenko GE, Gibson JK, Shinabarger DL, Aristoff PA, Ford
CW, Tarpley WG. Oxazolidinones: a new class of antibacterials.
Curr Opin Pharmacol 2001; 1: 470–476.
13 Bassetti M, Di Biagio A, Cenderello G et al. Linezolid
treatment of prosthetic hip infections due to methicillin-resistant
Staphylococcus aureus (MRSA). J Infect 2001; 43: 148–149.
14 Rubinstein E, Cammarata S, Oliphant T et al. Linezolid (PNU-
100766) versus vancomycin in the treatment of hopitalized
patients with nosocomial pneumonia: a randomised, double
blind, multicenter study. Clin Infect Dis 2001; 32: 402–412.
15 Li Z, Willke RJ, Pinto LA et al. Comparison in length of hospital
stay for patients with known or suspected methicillin-resistant
Staphylococcus species infections treated with linezolid or
vancomycin: a randomised, multicenter trial. Pharmacotherapy
2001; 21: 263–274.
16 Ratlief DA. New initiative in the prevention and treatment of
graft infection. In: Earnshaw JJ, Murie JA, eds. The Evidence of
Vascular Surgery. TMF Publishing, 1999: 173–181. Chapter 27.
Accepted 10 April 2003
Methicillin-resistant Staphylococcus aureus Vascular Graft Infection 101
EJVES Extra, 2003
